Sms For Life (A): A Public-Private Collaboration To Prevent Stock-Outs Of Life Saving Marlaria Drugs In Africa Custom Case Solution & Analysis

1. Evidence Brief (Case Researcher)

Financial Metrics

• Project cost for pilot in Tanzania: $150,000 (excluding Novartis personnel time).
• Target: Reduce malaria stock-outs from 79% (baseline) to 0% in pilot districts.
• Novartis corporate social responsibility (CSR) budget: Significant, but internal competition for funding exists.

Operational Facts

• Technology: Simple SMS-based reporting system using existing mobile phone infrastructure.
• Scope: 129 health facilities in three pilot districts (Tanzania).
• Process: Health workers send weekly stock levels via SMS; central dashboard tracks data; district supervisors intervene when levels fall below threshold.
• Connectivity: Mobile network coverage in rural Tanzania is widespread, even where electricity is absent.

Stakeholder Positions

• Novartis (Management): Seeking measurable social impact; concerned about scalability and long-term sustainability without constant corporate oversight.
• Tanzanian Ministry of Health (MoH): Interested in efficiency gains but constrained by bureaucratic inertia and limited district-level resources.
• Health Workers: Skeptical of additional reporting burdens; require incentives or clear proof of benefit to maintain compliance.

Information Gaps

• Long-term maintenance costs post-pilot.
• Specific breakdown of Novartis versus MoH funding for full national rollout.
• Data on how much of the stock-out issue is due to supply chain logistics versus procurement/funding shortages.

2. Strategic Analysis (Strategic Analyst)

Core Strategic Question

Can a technology-enabled, low-cost logistics monitoring system scale to a national level without becoming a permanent financial dependency on a private corporation?

Structural Analysis

• Value Chain: The primary failure point is the last mile — the gap between district warehouses and remote clinics. SMS-for-Life provides visibility but does not solve the underlying transport or funding shortages.
• PESTEL: Political stability in Tanzania is favorable for public-private partnerships, but economic constraints limit the MoH from assuming full financial control of the platform.

Strategic Options

• Option 1: The NGO Hand-off. Transition the platform to an international NGO. Pros: Removes Novartis from operational burden. Cons: Risks losing the direct link to supply chain improvements.
• Option 2: Integration into MoH Core Systems. Train MoH staff to manage the platform entirely. Pros: Maximum sustainability. Cons: High risk of failure due to limited MoH technical capacity.
• Option 3: The Hybrid Public-Private Model. Novartis maintains the technology platform as a utility while the MoH manages the logistics response. Pros: Keeps the tech stable while forcing MoH accountability. Cons: Novartis remains tied to the project indefinitely.

Preliminary Recommendation

Pursue Option 3. The technology is too fragile for a full hand-off yet. Novartis must treat this as a multi-year infrastructure investment rather than a short-term pilot.

3. Implementation Roadmap (Implementation Specialist)

Critical Path

1. Phase 1 (Months 1-3): Formalize the Service Level Agreement (SLA) between Novartis and the MoH, defining responsibilities for hardware replacement and software updates.
2. Phase 2 (Months 4-9): Implement a train-the-trainer program for district supervisors to ensure the MoH owns the human-capital side of the intervention.
3. Phase 3 (Months 10-18): National rollout in phases, starting with districts with the highest current stock-out rates.

Key Constraints

• Incentive Misalignment: Health workers have no intrinsic motivation to report data if it does not lead to faster drug delivery.
• Infrastructure: The system relies on mobile networks; if the network fails, the reporting loop breaks.

Risk-Adjusted Strategy

Build a manual reporting contingency for every district. If the SMS system fails for two consecutive weeks, district supervisors must conduct physical site checks. This prevents the technology from becoming a single point of failure.

4. Executive Review and BLUF (Executive Critic)

BLUF

Novartis should not attempt a national rollout until the pilot proves that increased visibility leads to actual drug availability. The current plan assumes that if you count it, they will come. That is a flawed premise. The project is currently a data-gathering exercise, not a supply-chain solution. Novartis must shift the focus from reporting the stock-out to financing the emergency transport needed to bridge the stock-out. Without funding the actual delivery of drugs, the SMS system is merely a mechanism to alert the government to failures they are already aware of but cannot afford to fix. Proceed only if the MoH commits to a dedicated transport budget for stock-outs identified by the system.

Dangerous Assumption

The assumption that the Ministry of Health has the physical logistics capacity to respond to the alerts generated by the SMS system. Visibility is not a substitute for transportation capability.

Unaddressed Risks

• Political Risk: The MoH may use the data to highlight failures to secure more donor funding rather than improving internal operations.
• Technical Obsolescence: The system architecture may not support the data volume of a national rollout without significant investment.

Unconsidered Alternative

Focus on a private-sector logistics partnership (e.g., local trucking firms) to handle the last-mile delivery, bypassing the inefficient MoH distribution network entirely.

Verdict

REQUIRES REVISION

The Strategic Analyst must address the "So-What" of the data. If the MoH cannot fulfill the orders, the SMS system is a vanity metric. Revise the strategy to include a logistics-fulfillment component.